Form EFFECT Tempest Therapeutics,
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 7, 2026 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang
- Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
- PROJECT HEALTHY MINDS SETS THE STAGE FOR ITS FOURTH ANNUAL WORLD MENTAL HEALTH DAY GALA ON OCTOBER 8TH AND FIFTH ANNUAL WORLD MENTAL HEALTH DAY FESTIVAL ON OCTOBER 10TH; SIGNATURE EVENTS TO BE HELD AT
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
